Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.61 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6980024 | 0.89 | EGFR (0.60) | EGFRERBB2GAKERBB4 | |
| SCHEMBL13814707 | 0.89 | EGFR (0.62) | EGFRERBB2GAKERBB4 | |
| SCHEMBL12094784 | 0.89 | EGFR (0.60) | EGFRERBB2ERBB4 | |
| SCHEMBL13889686 | 0.89 | EGFR (0.61) | EGFRERBB2GAKERBB4 | |
| SCHEMBL233913 | 0.88 | EGFR (0.77) | EGFRERBB2GAKERBB4 | |
| SCHEMBL9975296 | 0.87 | ERBB2 (0.60) | EGFRERBB2GAKERBB4 | |
| SCHEMBL13889772 | 0.87 | EGFR (0.70) | EGFRERBB2GAKERBB4 | |
| SCHEMBL12094765 | 0.87 | EGFR (0.53) | EGFRERBB2GAK | |
| SCHEMBL6976383 | 0.86 | EGFR (0.69) | EGFRERBB2GAKERBB4 | |
| SCHEMBL6979780 | 0.86 | EGFR (0.59) | EGFRERBB2GAKERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044063-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-25 | — | — | US | disclosed |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | NQO2, AQP3, AQP1 | EGFR 2954/4885ERBB2 2993/4885GAK 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.